PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
-
Iran says to oversee Hormuz as Swiss talks conclude
-
Diaspora World Cup champions diversity over division
-
Guns, drones and doves: War reshapes Ukrainian jewellery scene
-
Australia withholds Pacific climate fund reports over risk of diplomatic 'damage'
-
Kenya police violence victims say compensation promise a 'smokescreen'
-
Indian startup head appointed as new WhatsApp boss
-
EU bets on digital euro to cut US tech addiction
-
Antetokounmpo joining Miami Heat in blockbuster: reports
-
Fineanganofo rethinks Newcastle move after All Blacks call-up
-
'Let's be realistic': Haaland cools Norway's World Cup expectations
-
Stocks fluctuate after Wall St sell-off, crude holds losses on peace talks
-
Lightning, downpour, a two-hour delay: bad weather hits the World Cup
-
Ultra-reclusive Turkmenistan slowly opens up to tourists
-
Two-goal Haaland fires Norway into World Cup last 32
-
Marc Bloch, historian and Resistance hero, joins France's Pantheon greats
-
Last one the best one? How Messi keeps doing it at World Cup
-
Ronaldo 'a role model' says Portugal coach after slow World Cup start
-
North Korea's Kim vows to accelerate military buildup
-
Savea 'embraces challlenge' of leading All Blacks towards World Cup
-
Latin America's resurgent right notches another win in Colombia
-
Mbappe scores twice as France beat Iraq at World Cup after two-hour storm delay
-
Trump threatens prison for damage to Washington Reflecting Pool
-
Shortages ease in Bolivia as protest roadblocks dismantled
-
World Cup exploits of Maradona and Messi have Argentina fans in raptures
-
North America LiberNovo Prime Sale Fully Launches June 23
-
Empire Metals Limited Announces Investor Presentation on Investor Meet Company
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 23
-
Who Is Really Influencing Trump Marijuana Rescheduling?
-
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds
-
Star Copper Extends Copper Creek Drill Hole Beyond Planned Depth After Intersecting Mineralized System
-
England 'can beat any opponent' at World Cup, says Rice
-
'Boston Tea Party' compensation claim to be displayed at UK exhibit
-
Alvarez says 'best for everyone' if he leaves Atletico
-
France-Iraq World Cup game suspended due to severe weather alert
-
Romanian parliament rejects liberal PM-designate
-
Maduro ouster put Venezuela on 'the right path': interim leader
-
Missed penalty spurred 'very angry' Messi to World Cup history
-
Shooting in Montreal, Canada leaves three dead including suspect
-
Oil falls as US waives Iranian sanctions and Nasdaq tumbles
-
Balogun chases 'inevitable' Messi in wild Golden Boot race
-
Belgium's Doku becomes father after World Cup controversy
-
Magic Messi makes World Cup history to send Argentina into last 32
-
French TV presenter stood down over Doku World Cup comments
-
Ghana coach Queiroz says playing England 'easiest' World Cup game
-
Messi sets World Cup scoring record with 17th goal
-
Former Bayern stalwart Demichelis takes over at RB Leipzig
-
Colombian leftist candidate calls for calm after post-vote violence
-
Britons cautiously optimistic after PM's resignation
-
Latest developments in Europe's heatwave
-
Draper makes winning return at Eastbourne with Murray on his side
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
